MP0423 / Molecular Partners, AGC Biologics, Novartis - LARVOL DELTA

"MP0423" (@AllbridgeCap)

Novartis announces collaboration with Molecular Partners to develop two DARPin therapies designed for potential use against COVID-19 (GlobeNewswire) - "Novartis and Molecular Partners AG today announced a collaboration in the form of an option and license agreement to develop, manufacture and commercialize Molecular Partners’ anti-COVID-19 DARPin® program, consisting of two therapeutic candidates, MP0420 and MP0423....Molecular Partners will conduct Phase 1 clinical trials for MP0420, expected to begin in November 2020, and perform all remaining preclinical work for MP0423 and Novartis will conduct Phase 2 and Phase 3 clinical trials....Novartis would be responsible for all further development and commercialization activities....Molecular Partners will receive an upfront payment of CHF 60 million, including equity. Molecular Partners will receive a further payment of CHF 150 million, upon Novartis electing to take up the option to both therapeutic candidates, and significant royalty on sales."

Licensing / partnership • New P1 trial • Infectious Disease • Novel Coronavirus Disease